National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 11/26/2021 release of VAERS data:

Found 210 cases where Location is U.S., Territories, or Unknown and Vaccine is COVID19 and Manufacturer is JANSSEN and Symptom is Guillain-Barre syndrome

Government Disclaimer on use of this data



Case Details

This is page 18 out of 21

Result pages: prev   9 10 11 12 13 14 15 16 17 18 19 20 21   next


VAERS ID: 1736740 (history)  
Form: Version 2.0  
Age: 66.0  
Sex: Male  
Location: Pennsylvania  
Vaccinated:2021-06-05
Onset:2021-06-05
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2021-09-27
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN 202A21A / 1 LA / IM

Administered by: Other       Purchased by: ?
Symptoms: Anal incontinence, Asthenia, Back pain, Dizziness, Dysphagia, Dyspnoea, Gait disturbance, Guillain-Barre syndrome, Hypoaesthesia, Hypoaesthesia oral, Laboratory test, Mastication disorder, Mobility decreased, Nausea, Neck pain, Pain, Paraesthesia
SMQs:, Anaphylactic reaction (broad), Acute pancreatitis (broad), Peripheral neuropathy (narrow), Anticholinergic syndrome (broad), Retroperitoneal fibrosis (broad), Parkinson-like events (broad), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Acute central respiratory depression (broad), Pulmonary hypertension (broad), Guillain-Barre syndrome (narrow), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Cardiomyopathy (broad), Demyelination (narrow), Vestibular disorders (broad), Arthritis (broad), Noninfectious diarrhoea (broad), Tendinopathies and ligament disorders (broad), Hypoglycaemia (broad), Immune-mediated/autoimmune disorders (narrow), Sexual dysfunction (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, 11 days
   Extended hospital stay? No
Previous Vaccinations: Pfizer : adverse reactions reported
Other Medications: None
Current Illness: None
Preexisting Conditions: Heart Disease
Allergies: Various
Diagnostic Lab Data: Various
CDC Split Type:

Write-up: 20 minutes after the vaccination begin having neck and back pains on the right side of the body. Pens and needles feeling through out body, weakness, dizzy, nausea, unsteady walking, face and tongue mouth went numb, Difficulty chewing and swallowing. Shooting pain throughout of body, lost the control of bowel. Catheter has been inserted. Unable to walk long distances, difficulty breathing. Was diagnosed with Gullain-barre syndrome.


VAERS ID: 1739936 (history)  
Form: Version 2.0  
Age: 30.0  
Sex: Male  
Location: Massachusetts  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2021-09-28
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN - / UNK - / -

Administered by: Other       Purchased by: ?
Symptoms: Blood folate, Blood pressure measurement, Blood sodium, Blood thyroid stimulating hormone, CSF test, Drug screen, Drug screen positive, Guillain-Barre syndrome, Haematocrit, Haemoglobin, Heart rate, Inappropriate antidiuretic hormone secretion, Liver function test, Magnetic resonance imaging head, Oxygen saturation, Polymerase chain reaction, Pseudohyponatraemia, Respiratory rate, Vitamin B12, White blood cell count
SMQs:, Peripheral neuropathy (narrow), Drug abuse and dependence (broad), Guillain-Barre syndrome (narrow), Hyponatraemia/SIADH (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: Bupropion
Current Illness: Alcohol use (on average, 6?8 beers per day); Anxiety; Depression; Marijuana use (daily).
Preexisting Conditions: Comments: The patient had been in a state of good health upon receipt of the vaccine 32 days prior.
Allergies:
Diagnostic Lab Data: Test Name: MRI brain; Result Unstructured Data: Evidence of focal enhancement; Test Name: Sodium; Result Unstructured Data: 134 mEq/L; Test Name: CSF test; Result Unstructured Data: Albuminocytological dissociation; Comments: Glucose of 73 mg/dL, an elevated protein to 181 mg/dL and 7 nucleated cells/high-power field (HPF; corrected for 2987 red blood cells/HPF), constituting albuminocytological dissociation.; Test Name: Blood pressure; Result Unstructured Data: 218/80 mmHg; Test Name: Heart rate; Result Unstructured Data: 85 {beats}/min; Test Name: Respiratory rate; Result Unstructured Data: 16 {breaths}/min; Test Name: Oxygen saturation; Result Unstructured Data: 100 %; Test Name: White blood cell count; Result Unstructured Data: 12.25 10*3/mL; Test Name: Hemoglobin; Result Unstructured Data: 16.7 g/dL; Test Name: Hematocrit; Result Unstructured Data: 49.5 L/L; Test Name: Liver function test; Result Unstructured Data: Within normal limits; Test Name: Thyroid stimulating hormone; Result Unstructured Data: Within normal limits; Test Name: Folate; Result Unstructured Data: Within normal limits; Test Name: Vitamin B12; Result Unstructured Data: Within normal limits; Test Name: Urine drug screen; Result Unstructured Data: Positive for tetrahydrocannabinol; Test Name: PCR; Result Unstructured Data: Negative; Test Name: Sodium; Result Unstructured Data: 124 mEq/L, Hyponatremia; Test Name: MRI brain; Result Unstructured Data: Bilateral enhancement of the cisternal segments of trigeminal nerves.
CDC Split Type: USJNJFOC20210941304

Write-up: SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE; PSEUDOHYPONATREMIA; URINE TOXICOLOGY/ URINE DRUG SCREEN TEST POSITIVE FOR TETRAHYDROCANNABINOL; ATYPICAL GUILLAIN-BARRE SYNDROME; This spontaneous report was received from literature: Guillain-Barre Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report. The Journal of Emergency Medicine. 2021 Aug 07;1-5. This report concerned a 38-year-old male of unspecified race and ethnic origin. The objective of this report was to describe a case of an atypical presentation of GBS (Guillain-Barre Syndrome) presenting with extremity paresthesias, dysarthria, and bilateral facial weakness in the absence of classic ascending limb weakness, and discuss differential diagnosis, triage, and management. The patient''s height, and weight were not reported. The patient''s concurrent conditions included: Anxiety, depression, alcohol user (average of 6 to 8 beers per day), and marijuana user (daily). The patient had been in a state of good health upon receipt of the vaccine 32 days prior. The patient received covid-19 vaccine adv26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown, expiry: UNKNOWN) dose, start therapy date were not reported, 1 total administered for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included bupropion for anxiety and depression. On an unspecified date, approximately 2 weeks after vaccination, the patient experienced subacute, rapidly progressive, numbness and tingling in the tongue, lips, bilateral hands and feet/ paresthesias. Two days prior to presentation the patient began to develop difficulty moving his mouth, forming words/ dysarthria/slurred speech, bilateral facial weakness/ facial diplegia/bilateral facial nerve palsy in a lower-motor-neuron pattern with acral paresthesias variant and an absence of classic ascending limb weakness, as well as difficulty drinking from a straw and controlling the lips, cheeks and tongue while eating. The review of systems was notable for headaches, mild gait unsteadiness, generalized fatigue and dyspnea on exertion. The patient denied diplopia, dysphagia, or dysphonia, chest pain or palpitations, lightheadedness, fevers or chills, nausea, vomiting or diarrhea, urinary or bowel incontinence and falls or other trauma. The patient visited the emergency department in a clinically good condition, not in acute distress and was ambulating independently. Initial vital signs were as follows, blood pressure 218/80 mmHg, heart rate 85 beats/min, respiratory rate 16 breaths/min and oxygen saturation of 100%. The patient exhibited weak eye closure bilaterally and inability to smile or puff cheeks against resistance. The extraocular movements were intact and tongue was midline without fasciculations. Strength in the upper and lower extremities were intact (5/5) as sensation to light touch throughout. There was no dysmetria or gait ataxia. Deep tendon reflexes were reduced 1 plus in the lower extremities and only faintly present in the bilateral upper extremities. Laboratory data were notable for a white blood cell count of 12.25 x 10E3/mL with a normal differential, hemoglobin of 16.7 gram per deciliter, and a hematocrit of 49.5 L/L. The serum chemistries including liver function test, thyroid-stimulating hormone, folate, and B12 (Cobalamin), were all within normal limits. Urine toxicology/ Urine drug screen test was positive for tetrahydrocannabinol and covid-19 polymerase chain reaction was negative. A neurology consultation was obtained. The brain magnetic resonance imaging (MRI) with and without contrast and constructive interference in steady state (CISS) sequencing revealed focal enhancement of the bilateral internal auditory canal fundi which carried the CN-VII (cranial nerve) and CN-VIII and the bilateral cisternal segments of the trigeminal nerves. Cerebrospinal fluid (CSF) analysis revealed glucose of 73 mg/dL, an elevated protein to 181 mg/dL, and 7 nucleated cells/high-power field (HPF; corrected for 2987 red blood cells/HPF), constituting albuminocytological dissociation suggestive of atypical Guillain-Barre syndrome. The electrodiagnostic evaluation was not performed as the CSF profile and clinical presentations were definitive of GBS. The patient was hospitalized and received intravenous immunoglobulin (IVIG) over 2 days to a total dose of 2 grams per kilo gram body weight, which showed a mild improvement in his symptoms. Measurements of negative inspiratory force was performed daily, and the patient had not developed any signs or symptoms of respiratory compromise. On hospital day 1, the patient developed new hyponatremia, which had reached a value of 124 mEq/L (milliequivalents per litre) during admission which was concluded to be multifactorial, attributed to pseudohyponatremia in the setting of IVIG as well as syndrome of inappropriate antidiuretic hormone in the setting of GBS. The patient was treated with fluid restriction and salt tabs with improvement in sodium to 134 mEq/L on discharge. The patient''s symptoms showed no further progression and was discharged home on hospital day 4. The duration of hospitalization were 4 days. The discharge examination was notable for stable to improvement in bilateral facial weakness and dysarthria with generalized areflexia. The author concludes that the patient received the Johnson and Johnson vaccine against the COVID-19 virus 32 days prior to presentation. In the Johnson and Johnson COVID19 vaccine trial, one case of GBS in the post-vaccination arm was reported, however, there was also a case of GBS in the placebo arm. This did not imply a causal association between the Johnson and Johnson COVID-19 vaccine and GBS. Author cannot say definitively whether the patient''s prior vaccination contributed to his development of GBS or was incidental to it. The risk of developing vaccine-associated GBS remains very low when viewed across the general population, and cases of GBS with a temporal association to vaccination are not necessarily caused by a vaccine-mediated immune response. Overall, the benefits of vaccination to prevent COVID-19 infection likely outweigh the risks of any potential adverse effects, including GBS, as stated in recent guidelines from the centers for disease control and world health organization. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from syndrome of inappropriate antidiuretic hormone, pseudohyponatremia, and atypical Guillain-Barre syndrome, and the outcome of urine toxicology/ urine drug screen test positive for tetrahydrocannabinol was not reported. This report was serious (Hospitalization Caused / Prolonged).; Sender''s Comments: V0: 20210941304-covid-19 vaccine ad26.cov2.s- pseudohyponatremia, syndrome of inappropriate antidiuretic hormone, Urine toxicology/ Urine drug screen test positive for tetrahydrocannabinol. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). 20210941304-covid-19 vaccine ad26.cov2.s-atypical Guillain-Barre syndrome. This event(s) is labeled per RA and is therefore considered potentially related.


VAERS ID: 1739963 (history)  
Form: Version 2.0  
Age:   
Sex: Unknown  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2021-09-28
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN UNKNOWN / UNK - / -

Administered by: Other       Purchased by: ?
Symptoms: Guillain-Barre syndrome
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: USJNJFOC20210949856

Write-up: Guillain Barre syndrome; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age, sex with unspecified race and ethnic origin. The patient''s height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported, 1 total for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. As per the reporter, "Cousin had JnJ vaccine four months later and had been diagnosed with Guillan Barre." The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of guillain barre syndrome was not reported. This report was serious (Other Medically Important Condition). This case, from the same reporter is linked to 20210949880.; Sender''s Comments: V0- 20210949856- covid-19 vaccine ad26.cov2.s Guillain barre syndrome. This event(s) is labeled per RSI and is therefore considered potentially related.


VAERS ID: 1741279 (history)  
Form: Version 2.0  
Age: 61.0  
Sex: Male  
Location: Texas  
Vaccinated:2021-05-28
Onset:2021-06-21
   Days after vaccination:24
Submitted: 0000-00-00
Entered: 2021-09-28
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN 1816022 / 1 UN / IM

Administered by: Pharmacy       Purchased by: ?
Symptoms: Ageusia, Anosmia, Bell's palsy, Bowel movement irregularity, Dysarthria, Guillain-Barre syndrome, Laboratory test
SMQs:, Peripheral neuropathy (narrow), Taste and smell disorders (narrow), Guillain-Barre syndrome (narrow), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Demyelination (narrow), Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (broad), Hearing impairment (broad), Noninfectious diarrhoea (broad), Hypoglycaemia (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? No
Previous Vaccinations: Flu Vaccine
Other Medications: Advil
Current Illness: None
Preexisting Conditions: None
Allergies: None
Diagnostic Lab Data: Various Test Ran
CDC Split Type:

Write-up: Was diagnosed on 06/21/2021 with Bells Palsy and it affected the right side of his face causing slurring of words, lost of taste and smell. Has been told by doctor that he may have Guillain-Barr? syndrome. No bowel movement.


VAERS ID: 1743454 (history)  
Form: Version 2.0  
Age: 43.0  
Sex: Male  
Location: California  
Vaccinated:0000-00-00
Onset:2021-04-01
Submitted: 0000-00-00
Entered: 2021-09-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN 1808982 / UNK - / -

Administered by: Other       Purchased by: ?
Symptoms: Guillain-Barre syndrome
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, 5 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: USJNJFOC20210943950

Write-up: GUILLAIN BARRE SYNDROME; This spontaneous report received from a patient concerned a 43-year-old male of unspecified race. The patient''s weight was 147 pounds, and height was 67 inches. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, and batch number: 1808982 expiry: unknown) dose was not reported, 01 total, administered on 09-APR-2021 on left arm for prophylactic vaccination. No concomitant medications were reported. In APR-2021, 3 weeks post vaccination, the patient started experiencing symptoms like muscle pain all over the body, his feet felt like he had walked for miles, the bottom of his feet and fingers felt numb, he felt tingling and numbness that was getting worse, his legs started to feel numb; and arms and hands also started to feel the same. He tried to remember what he ate and what he did and may be what was causing the symptoms, he was finding it hard to do his job. On 23-JUL-2021, the patient visited the emergency room and was diagnosed with Guillain Barre syndrome was hospitalized for 5 days and discharged on 28-Jul-2021. Patient was administered unspecified treatment medication and did not remember what it was. The patient''s symptoms were not resolved and he also reported that he felt worse when he laid down and was unable to sleep. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from guillain barre syndrome. This report was serious (Hospitalization Caused / Prolonged).; Sender''s Comments: V0: 20210943950-COVID-19 VACCINE AD26.COV2.S- Guillain barre syndrome. This event is labeled per RSI and is therefore considered potentially related.


VAERS ID: 1749826 (history)  
Form: Version 2.0  
Age: 63.0  
Sex: Female  
Location: Michigan  
Vaccinated:2021-03-24
Onset:2021-03-26
   Days after vaccination:2
Submitted: 0000-00-00
Entered: 2021-09-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN 18080609 / 1 LA / IM

Administered by: Private       Purchased by: ?
Symptoms: Blood gases, Blood test, Computerised tomogram head, Dehydration, Echocardiogram, Electrocardiogram, Electroencephalogram, Feeding disorder, Guillain-Barre syndrome, Infusion, Magnetic resonance imaging head, Respiratory viral panel, Scan brain, Staphylococcal infection, Tremor, Urine analysis, Wound, Wound drainage
SMQs:, Peripheral neuropathy (narrow), Hyperglycaemia/new onset diabetes mellitus (broad), Neuroleptic malignant syndrome (broad), Parkinson-like events (broad), Guillain-Barre syndrome (narrow), Noninfectious encephalopathy/delirium (broad), Accidents and injuries (broad), Demyelination (narrow), Hypoglycaemia (broad), Infective pneumonia (broad), Dehydration (narrow), Opportunistic infections (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, 5 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: Carbidopa and levodopa 25/100mg 3 in AM 5 more times daily at 2.5, 50/200 mg ER once twice a day, Pramipexole 15mg 1 tablet 3 times a day, Entacapone 200mg 1 tablet 5 times a day, Mycophenolate 500 mg 2 tablets twice a day, Levothyroxine 10
Current Illness: No
Preexisting Conditions: Thyroid, Parkinson, CIDP, Lymphoedema no medicine Cancer Survivor and Knee replacement
Allergies: Cats, Seasonal allergies no medicines.
Diagnostic Lab Data: Blood test, brain scan, Heart test, stroke test, Echo Service, MRI Brain EEG, Adult Routine, Respiratory Virus Panel, Blood Gas, CT Head, Urine Analysis, EKG 12 Lead
CDC Split Type: vsafe

Write-up: 03/24/2021 Patient had open wound that was draining and it was not diagnosed at the time of the vaccination. Six days later it was diagnosed as staff infection 03/30/2021 09:00 AM prescribed antibiotics for days and she was not able to eat and drink, became dehydrated and had violent shakes. Was sent to the hospital, tests performed by Doctors. Had a GBS 03/09/2021 prior to vaccination then after the vaccination on 03/29/2021 infusion. Nursing home facility for 1 month after the hospital.


VAERS ID: 1750008 (history)  
Form: Version 2.0  
Age: 55.0  
Sex: Female  
Location: Minnesota  
Vaccinated:2021-03-25
Onset:2021-05-01
   Days after vaccination:37
Submitted: 0000-00-00
Entered: 2021-09-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN 1805018 / 1 RA / IM

Administered by: Private       Purchased by: ?
Symptoms: Anti-ganglioside antibody, Antiacetylcholine receptor antibody, Antinuclear antibody, Blood magnesium, Condition aggravated, Electromyogram normal, Glycosylated haemoglobin, Guillain-Barre syndrome, Lyme disease, Magnetic resonance imaging normal, Methylmalonic aciduria, Muscle tightness, Myelitis transverse, Paraesthesia, Red blood cell sedimentation rate, Tinnitus, Vitamin B12
SMQs:, Peripheral neuropathy (narrow), Congenital, familial and genetic disorders (narrow), Dystonia (broad), Guillain-Barre syndrome (narrow), Demyelination (narrow), Hearing impairment (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? No
Previous Vaccinations:
Other Medications: Zyrtec; Levothyroxine; Paxil; Symbicort; Albuterol
Current Illness: none
Preexisting Conditions: asthma; allergies; hypothyroidism - corrected with meds
Allergies: sulfa drugs, penicillin, contrast dye
Diagnostic Lab Data: EMG - June 14 - normal; MRI of cervical spine July 27 - normal, aside from age related degeneration; All of the following labs were normal and done in June: Lyme Disease, Methylmalonic Acid, B12, Ganglioside Antibodies, Ertyhrocyte Sed Rate, magnesium, Acetylcholine receptor binding, Hemoglobin A1C; These tests were abonormal: CK Total - high; ANA - was mildly positive and retested in the normal range
CDC Split Type:

Write-up: 6 weeks post-vaccination experienced consistent tingling in feet. 8 weeks post vaccination, pins and needles and tingling in both arms from hands to elbows and in both legs from feet to knees. Tinnitus that I have had for years also became louder. Muscle tightness in calves and backs of arms and lower back muscles on either side of spine very tight at all times. These symptoms are still present today. Was diagnosed with a variant of Guillain Barre or Transverse Myelitis. Neurologist would not confirm that this is due to COVID shot - he stated, "we just don''t know."


VAERS ID: 1750011 (history)  
Form: Version 2.0  
Age: 32.0  
Sex: Female  
Location: New York  
Vaccinated:2021-09-24
Onset:2021-09-24
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2021-09-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN - / 1 LA / IM

Administered by: Private       Purchased by: ?
Symptoms: Asthenia, Computerised tomogram, Dyspnoea, Electrocardiogram, Eye pain, Gait inability, Guillain-Barre syndrome, Headache, Hypoaesthesia, Lumbar puncture, Magnetic resonance imaging, Mobility decreased, Paraesthesia, Scan with contrast, Vision blurred
SMQs:, Anaphylactic reaction (broad), Peripheral neuropathy (narrow), Anticholinergic syndrome (broad), Dystonia (broad), Parkinson-like events (broad), Acute central respiratory depression (broad), Pulmonary hypertension (broad), Guillain-Barre syndrome (narrow), Glaucoma (broad), Cardiomyopathy (broad), Demyelination (narrow), Lens disorders (broad), Retinal disorders (broad), Tendinopathies and ligament disorders (broad), Hypoglycaemia (broad), Immune-mediated/autoimmune disorders (narrow), Sexual dysfunction (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? No
Previous Vaccinations:
Other Medications: Motegrity, constipend, probiotic, vitamin c,claritin, famotide
Current Illness: none
Preexisting Conditions: celiac disease
Allergies: celiac disease, penicillin
Diagnostic Lab Data:
CDC Split Type:

Write-up: On 9/24 at 5:40pm both my arms and legs started to fall asleep, get numb and tingle. I was unable to walk or move my arms properly. I started to have shortness of breathe and blurry vision as well as pain when moving my eyes. I had a severe headache. I went to the ER and was told this was a reaction to the COVID-19 vaccine and recieved two CAT scans and an EKG. I saw a neurologist that same evening on 9/24 who diagnoased weakness and parathesia in my limbs. Today, 9/30 I still have numbness and tingling in my arms and pain when moving my eyes. I saw the neurologist again today and she stated these are symptoms of gullian barre from the Janssen vaccine. She has ordered several MRI scans with dye and a spinal tap.


VAERS ID: 1751726 (history)  
Form: Version 2.0  
Age:   
Sex: Unknown  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2021-10-01
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN - / UNK - / -

Administered by: Other       Purchased by: ?
Symptoms: Guillain-Barre syndrome
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: USJNJFOC20210944284

Write-up: GUILLAIN- BARRE SYNDROME; This spontaneous report received from consumer via social media from another pharmaceutical company concerned multiple patients. The patients height and weight were not reported. No past medical history or concurrent conditions were reported. The patients all received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported 1 total administered for prophylactic vaccination. The batch numbers were not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On an unspecified date, the patients experienced Guillain-Barre Syndrome. The reporter stated that "the total data of adverse events from Vaccine Adverse Event Reporting System, comprising of all age groups from 14-DEC-2020 to 13-AUG-2021, showed 522 case reports of Guillain-Barre Syndrome out of which 25 percent of cases were attributed to use of JANSEEN COVID-19 VACCINE". No further details were reported. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of Guillain-Barre Syndrome was not reported. This report was serious (Other Medically Important Condition). This case, from the same reporter is linked to 20210957248, 20210957269, 20210957261 and 20210957342.; Sender''s Comments: V0- 20210944284- covid-19 vaccine ad26.cov2.s Guillain barre syndrome. This event(s) is labeled per RSI and is therefore considered potentially related.


VAERS ID: 1757010 (history)  
Form: Version 2.0  
Age: 34.0  
Sex: Female  
Location: Minnesota  
Vaccinated:2021-05-28
Onset:2021-07-06
   Days after vaccination:39
Submitted: 0000-00-00
Entered: 2021-10-02
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (JANSSEN)) / JANSSEN - / 1 LA / IM

Administered by: Military       Purchased by: ?
Symptoms: Guillain-Barre syndrome, Neurological symptom
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, 7 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type:

Write-up: Stroke like symptoms leading to hospitalization . Diagnosed with GBS. Continuing to have issues to present day with no explaination.


Result pages: prev   9 10 11 12 13 14 15 16 17 18 19 20 21   next

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=18&SYMPTOMS=Guillain-Barre_syndrome_%2810018767%29&VAX=COVID19&VAXMAN=JANSSEN&STATE=NOTFR


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166